Integrated non-invasive system for quantifying secreted human therapeutic hIL2

Biotechnology and Bioengineering

Volumn 95, Issue 5, 2006, Pages 938-945

  Chong, Wing Yung ^a   Barbari, Timothy A ^a   Bentley, William E ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

Author keywords

Bicistronic; Cell encapsulation; Destabilized DsRed Express; Fluorescence; Human interleukin 2

Indexed keywords

BLOOD; CELLS; DISEASES; FLUORESCENCE; PATIENT TREATMENT; TISSUE;

BICISTRONIC; CELL ENCAPSULATION; DESTABILIZED DSRED EXPRESS; HUMAN INTERLEUKIN-2;

PROTEINS;

CELL MARKER; DS RED EXPRESS FLUORESCENT PROTEIN; INTERLEUKIN 2;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ARTICLE; BLOOD SAMPLING; CELL ENCAPSULATION; CELL STRAIN HEK293; CELL SUSPENSION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DEVICE; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INFRARED RADIATION; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; RED LIGHT;

ANIMALS; ARTIFICIAL ORGANS; GENE EXPRESSION; GENES, REPORTER; GENETIC VECTORS; HUMANS; INTERLEUKIN-2; JURKAT CELLS; KIDNEY; LUMINESCENT PROTEINS; MICE; RECOMBINANT PROTEINS; TRANSFECTION;

MAMMALIA;

EID: 33845255742     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21064     Document Type: Article

References (37)

1. Aebischer P, Buchser E, Joseph JM, Favre J, de Tribolet N, Lysaght M, Rudnick S, Goddard M. 1994. Transplantation in humans of encapsulated xenogeneic cells without immunosuppression. A preliminary report. Transplantation 58(11):1275-1277.
2. Aebischer P, Pochon NA, Heyd B, Deglon N, Joseph JM, Zurn AD, Baetge EE, Hammang JP, Goddard M, Lysaght M, et al. 1996. Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF. Hum Gene Ther 7(7):851-860.
3. Bubenik J. 2004. Interleukin-2 therapy of cancer. Folia Biol (Praha) 50(3-4):120-130.
4. Campbell RE, Tour O, Palmer AE, Steinbach PA, Baird GS, Zacharias DA, Tsien RY. 2002. A monomeric red fluorescent protein. Proc Natl Acad Sci USA 99(12):7877-7882.
5. Cha HJ, Gotoh T, Bentley WE. 1997. Simplification of titer determination for recombinant baculovirus by green fluorescent protein marker. Biotechniques 23(5):782-784, 786.
6. Cha HJ, Dalal NG, Pham MQ, Bentley WE. 1999a. Purification of human interleukin-2 fusion protein produced in insect larvae is facilitated by fusion with green fluorescent protein and metal affinity ligand. Biotechnol Prog 15(2):283-286.
7. Cha HJ, Dalal NG, Vakharia VN, Bentley WE. 1999b. Expression and purification of human interleukin-2 simplified as a fusion with green fluorescent protein in suspended Sf-9 insect cells. J Biotechnol 69(1):9-17.
8. Chang TM. 2005. Therapeutic applications of polymeric artificial cells. Nat Rev Drug Discov 4(3):221-235.
9. Desai TA, West T, Cohen M, Boiarski T, Rampersaud A. 2004. Nanoporous microsystems for islet cell replacement. Adv Drug Deliv Rev 56(11):1661-1673.
10. Eklund JW, Kuzel TM. 2004. A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol 16(6):542-546.
11. El-Aneed A. 2004. An overview of current delivery systems in cancer gene therapy. J Control Release 94(1):1-14.
12. Gelman MS, Kannegaard ES, Kopito RR. 2002. A principal role for the proteasome in endoplasmic reticulum-associated degradation of misfolded intracellular cystic fibrosis transmembrane conductance regulator. J Biol Chem 277(14):11709-11714.
13. Hauser O, Prieschl-Grassauer E, Salmons B. 2004. Encapsulated, genetically modified cells producing in vivo therapeutics. Curr Opin Mol Ther 6(4):412-420.
14. Heikal AA, Hess ST, Baird GS, Tsien RY, Webb WW. 2000. Molecular spectroscopy and dynamics of intrinsically fluorescent proteins: coral red (dsRed) and yellow (Citrine). Proc Natl Acad Sci USA 97(22):11996-12001.
15. Hess ST, Sheets ED, Wagenknecht-Wiesner A, Heikal AA. 2003. Quantitative analysis of the fluorescence properties of intrinsically fluorescent proteins in living cells. Biophys J 85(4):2566-2580.
16. Jacobson EL, Pilaro F, Smith KA. 1996. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA 93(19):10405-10410.
17. Jakobs S, Subramaniam V, Schonle A, Jovin TM, Hell SW. 2000. EFGP and DsRed expressing cultures of Escherichia coli imaged by confocal, two-photon and fluorescence lifetime microscopy. FEBS Lett 479(3):131-135.
18. Jimenez C, Moran SA, Sereti I, Wynne S, Yen PM, Falloon J, Davey RT, Sarlis NJ. 2004. Graves' disease after interleukin-2 therapy in a patient with human immunodeficiency virus infection. Thyroid 14(12):1097-1102.
19. Kaplan G, Cohn ZA, Smith KA. 1992. Rational immunotherapy with interleukin 2. Biotechnology (NY) 10(2):157-162.
20. Kizilel S, Garfinkel M, Opara E. 2005. The bioartificial pancreas: progress and challenges. Diabetes Technol Ther 7(6):968-985.
21. Kozak M. 1987. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 15(20):8125-8148.
22. Li X, Zhao X, Fang Y, Jiang X, Duong T, Fan C, Huang CC, Kain SR. 1998. Generation of destabilized green fluorescent protein as a transcription reporter. J Biol Chem 273(52):34970-34975.
23. Martin BK, Wu AW, Gelman R, Mitsuyasu RT. 2005. Quality of life in a clinical trial of highly active antiretroviral therapy alone or with intravenous or subcutaneous interleukin-2 administration. J Acquir Immune Defic Syndr 40(4):428-433.
24. McDermott DF, Atkins MB. 2004. Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther 4(4):455-468.
25. Meyer MP, Smith SJ. 2006. Evidence from in vivo imaging that synaptogenesis guides the growth and branching of axonal arbors by two distinct mechanisms. J Neurosci 26(13):3604-3614.
26. Mizuno H, Sawano A, Eli P, Hama H, Miyawaki A. 2001. Red fluorescent protein from Discosoma as a fusion tag and a partner for fluorescence resonance energy transfer. Biochemistry 40(8):2502-2510.
27. Orive G, Hernandez RM, Rodriguez Gascon A, Dominguez-Gil A, Pedraz JL. 2003. Drug delivery in biotechnology: present and future. Curr Opin Biotechnol 14(6):659-664.
28. Porta C. 2006. Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer. Expert Rev Anticancer Ther 6(1):141-152.
29. Smith KA, Jacobson EL, Emert R, Giordano M, Kovacs E, Mumneh N, Pilaro F, Sohn T, Warren D. 1999. Restoration of immunity with interleukin-2 therapy. AIDS Read 9(8):563-572.
30. Stroncek DF, Burns C, Martin BM, Rossi L, Marincola FM, Panelli MC. 2005. Advancing cancer biotherapy with proteomics. J Immunother 28(3):183-192.
31. Valentina Ciccarone YC, Kevin S, Jean-Pierre Pichet PH-N, Krista E, Linda R, Shelley B. 1999. LIPOFECTAMINE™ 2000 Reagent: For rapid, efficient transfection of eukaryotic cells. Focus 21(2):54-55.
32. Vintersten K, Monetti C, Gertsenstein M, Zhang P, Laszlo L, Biechele S, Nagy A. 2004. Mouse in red: red fluorescent protein expression in mouse ES cells, embryos, and adult animals. Genesis 40(4):241-246.
33. Visted T, Lund-Johansen M. 2003. Progress and challenges for cell encapsulation in brain tumour therapy. Expert Opin Biol Ther 3(4):551-561.
34. Weiss A, Wiskocil RL, Stobo JD. 1984. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J Immunol 133(1):123-128.
35. Yamaguchi Y, Ohshita A, Kawabuchi Y, Ohta K, Shimizu K, Minami K, Hihara J, Miyahara E, Toge T. 2003. Adoptive immunotherapy of cancer using activated autologous lymphocytes - current status and new strategies. Hum Cell 16(4):183-189.
36. Zhuang X, Ha T, Kim HD, Centner T, Labeit S, Chu S. 2000. Fluorescence quenching: A tool for single-molecule protein-folding study. Proc Natl Acad Sci USA 97(26):14241-14244.
37. Zimmermann H, Zimmermann D, Reuss R, Feilen PJ, Manz B, Katsen A, Weber M, Ihmig FR, Ehrhart F, Gessner P, et al. 2005. Towards a medically approved technology for alginate-based microcapsules allowing long-term immunoisolated transplantation. J Mater Sci Mater Med 16(6):491-501.